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Metabolism of tryptophan along the kynurenine pathway yields multiple metabolites that 
collectively exhibit both a rich pharmacology and broad neurobiological significance 
(Schwarcz et al., 2012). This includes not just neurotoxic and neuroprotective metabolites 
that exert their influence via opposing action at NMDA receptors but also molecules with 
activity at metabotropic glutamate receptor subtypes, the aryl hydrocarbon receptor and 
specific G-protein coupled receptors (GPCRs) (Stone et al., 2013). Despite the therapeutic 
possibilities arising from this extensive pharmacological repertoire, kynurenines have 
struggled to reach equitable status in the scientific consciousness with other tryptophan 
metabolites such as serotonin and melatonin. The growing realisation that the sphere of 
influence of dysregulated metabolism extends to most fundamental aspects of brain function 
with manifestations possible across the life span has seen this imbalance somewhat rectified. 
Now that these metabolites are no longer neglected, it is not surprising that altered 
metabolism along this pathway has been associated with numerous psychiatric and 
neurological disorders. Indeed, the immunoresponsive and stress-reactive nature of 
kynurenine pathway enzymes has stimulated biomarker studies and brought into focus a 
number of appealing therapeutic targets of relevance across a wide swathe of pathologies. 
The pathway still holds much covert potential, however. Although there is now a solid grasp 
of several of its features and nuances, some metabolites and enzymes are still understudied. It 
is easy to predict that ongoing research will reveal new layers of complexity and provide 
fresh insights. 
This Special Issue of Neuropharmacology is an effort to provide a collection of articles to 
illustrate the research challenges and opportunities provided by our mounting but still 
incomplete knowledge of kynurenine pathway metabolism. Schwarcz and Stone (Schwarcz 
and Stone, 2016) chart the rise of the kynurenines from relative obscurity to their current 
prominence. This overview also illuminates the knowledge gaps to be bridged, and the 
pitfalls and promise inherent in this complex area of research. Clearly, an understanding of 
kynurenine pathway metabolism is contingent on a solid appreciation of the factors 
influencing the availability of tryptophan under both normal and pathological conditions 
(Badawy, 2015). Fujigaki and colleagues (Fujigaki et al., 2016) further elaborate on the 
mechanisms that regulate the expression and activity of pathway enzymes, with an emphasis 
on cell-type specific features of the metabolic cascade. 
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The implications of altered metabolism of tryptophan along the kynurenine pathway are 
manifold and may manifest across the life span. Notarangelo and Pocivavsek (Notarangelo 
and Pocivavsek, 2016) emphasise the important role of fluctuations in these neuroactive 
metabolites during critical neurodevelopmental windows, visible particularly in cognitive 
impairments expressed in adulthood following kynurenic acid modulation during gestation or 
postnatally. The role of the immune system in activating kynurenine pathway metabolism has 
implications for numerous disorders, particularly when viewed through the lens of infection-
mediated alterations in behaviour and the links between immune system malfunction and 
psychopathology (Erhardt et al., 2017; Strasser et al., 2016). Equally, activation of the 
kynurenine pathway by glucocorticoids is an important factor for many stress-related 
disorders (O'Farrell and Harkin, 2015). The possibility that kynurenine pathway metabolism 
could be implicated as a neurobiological factor underpinning suicidality has also received 
attention (Bryleva and Brundin, 2016). Finally, it is important to bear in mind that some 
kynurenines participate in redox reactions, and this may have repercussions for critical 
biological functions that malfunction in relevant pathologies (Gonzalez Esquivel et al., 2016). 
As research advances in this area and moves beyond more general concepts of pathway 
activation, it is clear that certain metabolites of the kynurenine pathway may hold special 
relevance for specific disorders. For example, research now associates the accumulation of 
quinolinic acid with amyotrophic lateral sclerosis (ALS) (Lee et al., 2016). In tandem, 
information about an expanding range of molecular targets continues to emerge for 
previously understudied metabolites including cinnabarinic acid as an orthosteric agonist of 
mGlu4 receptors and the activation of mGlu2 and mGlu3 receptors by xanthurenic acid 
(Fazio et al., 2016). Given the important role of metabotropic glutamate  receptors in the CNS 
as well as in peripheral and non-neural tissues, this is an especially promising avenue of 
investigation (for review see: (Julio-Pieper et al., 2011).  
These and other developments highlighting the therapeutic potential of targeting kynurenine 
pathway metabolism have encouraged evaluation of the kynurenine pathway in other 
neurological disorders such as multiple sclerosis as well as HIV-associated neurocognitive 
disorders (Lovelace et al., 2016). The CNS impact of parasitic diseases, such as malaria and 
toxoplasmosis, has also been considered in the context of their impact on kynurenine 
production (Hunt et al., 2016), and exciting emerging research supports a role for the gut 
microbiota in the regulation of kynurenine pathway metabolism (Kennedy et al., 2016).  
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Taken together, the breadth of these topics should make clear our motivation to put the 
kynurenine pathway under the spotlight in this Special Issue. The capacity of the kynurenines 
to surprise us should not be underestimated, and we hope that the insights in this compilation 
of articles will provide both stimulus and direction for ongoing research efforts and new 
researchers in the field. Now that consequences of the dysregulation of kynurenine pathway 
metabolism is more fully appreciated, and as the range of activity of the kynurenines is 
further teased apart, we can start to envisage the benefits of interventions that move us back 
towards metabolic equilibrium. 
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